Effects of Combined Resveratrol Plus Metformin Therapy in db/db Diabetic MiceDuarte-VÃ¡zquez Miguel Ãngel1,3, GÃ³mez-SolÃs MarÃa Antonieta2, GÃ³mez-Cansino Rocio2, Reyes-Esparza Jorge2, Jorge Luis Rosado1,3 and RodrÃguez-Fragoso Lourdes2*
- *Corresponding Author:
- Lourdes Rodríguez Fragoso
M.D, Ph.D, Faculty of Pharmacy
Autonomous University of the State of Morelos
Tel: (777) 3297000; Ext: 2321
E-mail: [email protected]
Received date: November 22, 2016; Accepted date: December 06, 2016; Published date: December 13, 2016
Citation: Ãngel DVM, Antonieta GSM, Rocio GC, Jorge RE, Rosado JL, et al. (2016) Effects of Combined Resveratrol Plus Metformin Therapy in db/db Diabetic Mice. J Metabolic Synd 5: 217. doi: 10.4172/2167-0943.1000217
Copyright: ©2016 Ãngel DVM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The worldwide prevalence of Type 2 diabetes mellitus is associated with other conditions that trigger metabolic syndrome. Although several studies on the benefits of resveratrol have been carried out, few have assessed this drug in combination with metformin. Objectives: This study looks at the effects that combined metformin/resveratrol therapy has on body weight gain and liver and renal damage of db/db diabetic mice. It also addresses biochemical findings. Method: Diabetic mice were treated with resveratrol (20 mg/kg/day), metformin (150 mg/kg/day) and combined metformin/resveratrol therapy for 5 weeks. Histopathological tissue analyses and biochemical parameters (glucose, insulin, triglycerides and cholesterol), functional liver enzymes (AP, AST and GGT) and renal parameters (urea and uric acid) were examined. Results: Our data clearly showed that combined metformin/resveratrol treatment reduced obesity, glucose and triglyceride levels, as well as improving renal function and partially improving liver function in diabetic mice. Conclusion: The combined therapy may enhance remedial effects in diabetic patients as well as in other metabolic disorders, such as metabolic syndrome.